Tris Pharma announced that the FDA has approved Clonidine ER suspension and Clonidine ER tablets, both of which utilize its proprietary OralXR+ platform technology to allow for once daily dosing. In addition to providing the option of 24-hour dosing and use in patients who have difficulty swallowing (eg, young children and the elderly), the liquid sustained-release formulation of Clonidine ER suspension allows healthcare providers the ability to customize the dose through titration.
Clonidine is a direct-acting alpha 2 adrenergic agonist indicated for the treatment of hypertension. Clonidine ER suspension will be available in a 0.09mg/mL strength formulation. Clonidine ER tablets will be available in 0.17mg and 0.26mg dosage strengths.
For more information call (732) 940-2800 or visit www.trispharma.com.